Markets DYAI

Dyadic (DYAI) Q3 2026 Earnings Call Transcript

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Thursday, Nov. 12, 2026

CALL PARTICIPANTS

  • Chief Financial Officer - Ping Wang Rawson
  • President and Chief Operating Officer - Joseph Hazelton
  • Chief Executive Officer - Mark A. Emalfarb

TAKEAWAYS

  • Total Revenue -- Approximately $449,000 for the third quarter, representing a 61% decrease driven by a $538,000 decline in grant revenue and lower R&D activity.
  • Grant Revenue -- $276,000 for the quarter, reflecting reduced activity under the Bill & Melinda Gates Foundation and CEPI programs compared to the prior year.
  • Net Loss -- $1.4 million, or $0.04 per share, compared to a net loss of $2 million, or $0.06 per share, in the third quarter of 2025.
  • Cash and Investment Position -- $6 million in cash, equivalents, and investment-grade securities as of Sept. 30, 2026, down from $8.6 million at year-end 2025.
  • Operating Cash Burn -- $5.3 million for the first nine months of 2026, averaging approximately $590,000 per month including costs for grant-funded programs.
  • Registered Direct Offering -- $2.9 million in gross proceeds generated during the third quarter through a registered direct offering with concurrent private placements of warrants.
  • Internal R&D Expenses -- Approximately $430,000, a 25% year-over-year decrease resulting from a $199,000 reduction in third-party contract research services.
  • G&A Expenses -- $1.45 million for the quarter, a 2% decrease compared to $1.48 million in the prior year period.
  • Enzymes Contractual Payment -- $225,000 expected in the fourth quarter of 2026 following the first commercial sale of a second chymosin product in October 2026.
  • Strive Nutrition Supply Agreement -- 10 tons of initial production with targets up to 100 tons in the following year, contingent on meeting economic and regulatory thresholds.
  • Gates Foundation Program Yields -- 12.1 grams per liter for RSV monoclonal antibody RSV-Mab1 and 13.2 grams per liter for malaria antibody Mab1 achieved in 7-day fermentations.
  • Vaccine Development Speed -- 15 days to progress from plasmid to purified recombinant protein, demonstrated during the Bundibugyo Ebola outbreak using the C1 platform.
  • Ebola Monoclonal Antibody Timeline -- 7 weeks from plasmid to clonal production strain and protein A purified antibody, providing an alternative to mammalian cell manufacturing.
  • CEPI/FBS Program Funding -- $4.5 million allocated for a rapid vaccine antigen development project using the C1 production workflow.
  • Vaccine Hub Initiative -- €170 million in consortium-level funding involving the evaluation of C1 within the European Vaccine Hub initiative.
  • Direct Product Sales -- Initial sales of recombinant transferrin and DNase 1 recorded in the third quarter, validating the C1 proprietary fungal expression system.
  • IBT Bioservices Distribution -- Six research-use-only recombinant protein products launched through a third-party distribution network to leverage established customer bases.
  • Warrant Liability Gain -- $546,000 non-cash net gain resulting from the change in fair value of warrant liability related to the August offering.
  • Glycan Structure Performance -- 90% human-like glycan structures achieved in C1-produced antibodies, supporting the platform's ability to produce complex monoclonal antibodies.
  • Nine-Month Financials -- $2.5 million in total revenue and a net loss of $5.4 million, or $0.15 per share, for the first three quarters of 2026.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Hazelton stated, "Our direct commercial sales remain modest, and customer qualification and adoption are taking longer than we originally anticipated," noting that regulatory hurdles and integration into customer workflows have slowed market penetration.
  • Hazelton warned that the company does not have enough capital to build significant inventory levels, stating that the organization is "making to demand right now" which has contributed to slower growth in the research segment.

SUMMARY

Dyadic International, Inc. (NASDAQ:DYAI) reported progress in its transition from a technology development entity to a commercial platform company through direct product sales and strategic partnerships. Management reported the first direct commercial sales of recombinant transferrin and DNase 1, while also expanding its distribution reach through third-party networks. The company indicated a strategic shift toward larger licensing and supply arrangements to leverage the manufacturing infrastructure of established partners and mitigate independent capital requirements. Financial performance for the third quarter was impacted by lower grant and research revenue, though operating losses narrowed compared to the prior year. Management is prioritizing externally funded development programs in the biopharmaceutical sector to validate its C1 platform for monoclonal antibodies and rapid vaccine production.

  • The company vertically integrated its alpha-lactalbumin partnership by adding Strive Nutrition as an end customer with national distribution in major retail channels.
  • Management reported that C1-produced monoclonal antibodies achieved productivity yields between 12.1 grams per liter and 13.2 grams per liter, which CEO Emalfarb noted were significantly higher than those typically produced in traditional mammalian CHO cells.
  • Pharmacokinetic animal studies for malaria and RSV antibodies are currently underway with results anticipated in the first quarter of 2027.
  • The company reduced its vaccine development timeline from months to 15 days, providing a rapid response capability for emerging infectious disease threats without using mRNA technology.
  • Management indicated that partner ProLiant Health and Biologics is expanding commercial applications for animal-free albumin into diagnostic assays and protein stabilization.
  • The company is evaluating financing alternatives and strategic transactions to strengthen its balance sheet while maintaining a disciplined monthly cash burn of approximately $590,000.

INDUSTRY GLOSSARY

  • C1 Platform: A proprietary fungal expression system based on the Thermothelomyces heterothallica fungus used for high-yield protein production.
  • DAPIBUS Platform: A fungal-based expression system designed for the production of enzymes and proteins for food, nutrition, and bioindustrial applications.
  • Transferrin: A glycoprotein used in cell culture media to transport iron to cells, which Dyadic produces recombinantly as an animal-free alternative.
  • Chymosin: An enzyme used in cheesemaking that Dyadic and its partners produce through precision fermentation.
  • Monoclonal Antibodies (mAbs): Laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens like viruses.
  • CHO Cells: Chinese Hamster Ovary cells, the industry standard mammalian cell line used for the production of therapeutic proteins.
  • Glycosylation: The process by which sugar molecules are attached to proteins, which is critical for the proper function of biopharmaceutical drugs.

Full Conference Call Transcript

Operator: Good evening and welcome to Dyadic International's Q3 26 Conference Call. Currently, participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question-and-answer session. As a reminder, this conference call is being recorded today, November 12, 2026. I would now like to turn the call over to Ms. Ping Wang Rawson, Dyadic's Chief Financial Officer. Please go ahead.

Ping Wang Rawson: Thank you. Good evening and welcome everyone to Dyadic's third quarter 26 Conference Call. I hope you have had the opportunity to review Dyadic's press release announcing financial results for the quarter ended September 2026. You may access our release under the Investors section of the company's website at dyadic.com. Before we begin, I want to let you know that due to a Microsoft Outlook issue that has impacted many organizations, including Dyadic, We have not yet filed our quarterly report on Form 10-Q for the quarter ended 09/30/2026. We expect to file the Form 10-Q as soon as the system is back online. And within the SEC filing deadline.

The financial results we will discuss today are those in our press release. They will be reflected in the Form 10-Q. On today's call, our President and Chief Operating Officer, Joe Hazleton, will review our Q3 26 business and corporate highlights. and provide a commentary on the strategic direction of the Our CEO, Mark Emalfarb will provide an update on our biopharmaceutical programs. and I will follow with a review of our financial results in more detail after which we will hold a brief question-and-answer session.

At this time, I would like to inform you that certain commentary made in this conference call may be considered forward looking statements which involve risks and uncertainties and other factors that could cause Dyadic's actual results performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward looking statements. Dyadic expressly disclaims any duty to provide updates to its forward looking statements. Whether because of new information, future events or otherwise. Participants are directed to the risk factors set forth in Dyadic's reports filed with the SEC. It is now my pleasure to pass the call to our President and COO, Joe Hazleton. Joe?

Joseph Hazelton: Thanks, Ping, and thank you, everyone, for joining us today. Over the past several quarters, we have discussed Dyadic's transition from primarily developing protein production technologies toward building commercial business around our C1 and DAPIBUS platforms. During the third quarter, we continued making progress in that transition through initial direct product sales broader distribution, additional partner commercialized products, and advancing discussions with companies interested in our technologies and protein production portfolio. While these developments are encouraging, I want to put them in perspective. Our direct commercial sales remain modest, and customer qualification and adoption are taking longer than we originally anticipated. While still. While we still have work ahead of us to establish meaningful and recurring product revenue.

However, we are beginning to demonstrate that our protein production platforms can support commercial products through multiple business models including direct sales, distribution, licensing, and partner led commercialization. And importantly, we believe our decades of commercial experience put us in a stronger position to pursue larger strategic opportunities. Now let's walk through some of the developments during the quarter and explain how they connect to our broader strategy. Starting with life sciences. During the third quarter, Dyadic recorded its first direct commercial protein product sales, primarily involving recombinant transferrin and DNase 1.

While these sales are not yet financially material, they further demonstrate that the Dyadic can develop and commercialize recombinant enzymes and proteins validating the potential of our proprietary fungal expression systems and complementing the products already being commercialized through our partners. Our immediate priority is to convert initial purchase and ongoing customer evaluations into repeat business. We continue to see increased sampling requests and customer evaluations particularly for human and bovine transferrin across research, cell culture, and cultured meat applications. Transferrin remains an important commercial focus because of its role in cell culture media and the potential demand for consistent animal free alternatives.

As we have discussed previously, improvements in production yields and manufacturing economics are important to making these products competitive. But the qualification process takes time for higher value segments like cell culture media. Customers need to establish that a replacement protein performs consistently in their specific applications meets their quality requirements, and can be supplied reliably at acceptable economics. We are supporting those evaluations and working to expand our customer base, but we recognize that the conversion from sampling to recurring purchase has been slower than anticipated. Alongside our direct sales efforts, we continue to expand our commercial reach through third party distribution.

IBT Bioservices has now launched an initial portfolio of 6 dyadic produced research use only recombinant protein products through its distribution network. This relationship provides access to an established customer base without requiring Dyadic to build a substantial direct sales organization. We are also evaluating additional products for distribution and pursuing opportunities with other distributors and commercial partners. Our objective remains to build a capital efficient commercial model that leverages established channels and partners. Another important part of our strategy is working with established companies that can take products developed using our platforms into their respective markets. ProLiant Health and Biologics continues to expand its commercial activities around AlbuFree DX, its recombinant human serum albumin produced using Dyadic C1 platform.

ProLiant has been presenting performance and analytical data supporting applications in diagnostic assays and protein stabilization and has outlined plans to introduce additional products targeting cell culture media, and cell and gene therapy applications. These activities provide an opportunity to expand the number of commercial applications for animal free albumin with potential future revenue participation for Dyadic under our commercial arrangements. In food and nutrition, our partner Enzymes has now commercialized its second Chymosin product using our DAPIBUS platform. In November, Enzymes informed us that its first commercial sale of DAPIBUS produced camel chymosin occurred in October. As a result, we expect to receive a $225,000 contractual payment and recognize the associated revenue during the fourth quarter.

This follows the earlier commercialization of bovine time and further demonstrates the ability to develop and commercialize different products using the DAPIBUS production system. What is particularly relevant about ProLiant enzymes is that these are established commercial organizations bringing products produced with the Dyadic technology to market. Although the revenue contribution to Dyadic remains at an early stage, these relationships provide evidence of commercial applicability that can be valuable evaluating broader licensing, supply, and strategic partnership opportunities. Also in our food nutrition business, alpha-lactalbumin remains 1 of our highest priority development and commercial opportunities. We continue to advance our collaboration with BRIG Bio to develop and scale DAPIBUS-produced bovine alphylacta albumin.

An animal free dairy protein with potential applications in nutritional products. Recently, we announced an expanded strategic collaboration with BRIG Bio and Strive Nutrition. Bringing together complementary capabilities across the entire value chain. From Dyadic's DAPIBUS protein production platform and strain optimization expertise, to manufacturing scale up commercialization and integration into finished consumer products. Importantly, this collaboration aligns protein development and manufacturing capabilities with Strive Nutrition, the intended end customer, which plans to integrate our precision fermented animal free alpha-lactalbumin into its next generation nutritional products. We believe this integrated approach provides a more direct pathway toward commercial scale production, market adoption, and potential recurring revenue opportunities.

Our technical focus remains on improving production yields protein quality, and manufacturing economics to support competitive commercial scale production. While we are encouraged by the progress, further optimization, application testing, regulatory work and scale up remain necessary before commercial production can be established. We are also continuing discussions with additional global companies regarding potential licensing, development, and commercial arrangements involving alpha lactalbumin, and other animal free proteins in our portfolio. These discussions are particularly relevant because the larger food and nutrition markets require manufacturing capacity, capital investment, regulatory expertise, and establish commercial distribution. Our strategy is to work with companies that already possess these capabilities rather than attempting to build the entire commercial infrastructure ourselves.

Beyond bovine alpha-lactalbumin, we have developed production strains for human alpha-lactalbumin and human lactoferrin and are actively exploring licensing and strategic partnership opportunities for these products. We have also initiated development of recombinant bovine lactoferrin further expanding our portfolio of animal free nutritional proteins. In addition, we continue to advance other dairy proteins and enzymes through internal development programs and external collaborations broadening the range of potential applications and commercial opportunities for our platforms. We believe this expanding portfolio combined with a growing interest from potential commercial partners positions Dyadic to pursue broader strategic relationships across the food nutrition market. In our bioindustrial segment, we continue to expand applications for DAPIBUS platform across industrial enzymes and biomass processing.

Our partner firm LuxBio has launched EN3ZYME, DAPIBUS-produced enzyme product targeting biomass processing applications. We are also developing additional enzymes for use across biofuels, food and feed, and textile and paper processing markets. We are seeing increased interest in EN3ZYME and other industrial enzyme solutions particularly in the biofuels and ethanol markets where volatility in energy markets is contributing to renewed interest in alternative fuels and improved production economics. This has translated into a significant increase in sampling activity and discussions with potential customers and strategic partners. We believe our ability to develop customized enzyme solutions combined with the manufacturing efficiency and scalability of DAPIBUS creates opportunities to address the evolving needs of these industries.

With our other commercial businesses, our focus is on working with partners that bring established manufacturing capabilities industry expertise, and customer relationships to accelerate commercialization while limiting the capital Dyadic would otherwise need to invest independently. When we look across our businesses, we believe the progress we have made in commercializing products both directly and through our partners is strengthening the strategic value of our C1 and DAPIBUS platforms. We now have several examples of our technology supporting commercial products and generating revenue through different business models. ProLiant has commercialized recombinant human albumin using C1. Enzymes has commercialized 2 chymosin products using DAPIBUS. An EN3ZYME has entered the industrial market.

These relationships demonstrate our ability to develop products that can be commercialized through established partners. More recently, our collaboration with BRIG Bio and Strive Nutrition brings together key elements of the commercial value chain for DAPIBUS-produced alpha-lactalbumin. From strain development and manufacturing scale up, through to Strive, the intended end customer. This vertically integrated partnership provides a defined pathway toward potential commercial supply subject to successful development, scale up, and product qualification. Together with our initial direct protein sales and expanding distribution network, we believe these developments provide meaningful progress and commercial validation of our platforms across life sciences, food and nutrition, and bioindustrial markets.

While commercial revenues are modest, we believe this growing track record helps us reduce the technical and commercial uncertainties that prospective strategic partners must evaluate. Placing Dyadic in a stronger position to pursue larger opportunities. This is increasingly where we intend to focus our efforts. Rather than independently funding the development and commercialization of every product, we believe greater value can be created by partnering with companies that have the capital, manufacturing infrastructure, and commercial capabilities to bring our technologies and markets products to market at scale. Accordingly, we are placing greater emphasis on larger strategic partnerships licensing and supply arrangements and other potential transactions involving our platforms, products, and commercial programs.

We continue to evaluate all options to maximize the value of our platforms and assets including financing alternatives, strategic partnerships, and other opportunities to strengthen our balance sheet. Accelerate commercialization, and support long term shareholder value. Our objective is to build on the commercial foundation we have established and translate that progress into larger opportunities that can deliver meaningful financial results for Dyadic and its shareholders. With that, I will now turn the call over to Mark to discuss our biopharmaceutical programs and the continuing development of our C1 platform. Mark?

Mark A. Emalfarb: Thank you, Joe. Biopharmaceutical development validation and strategic operations, and opportunities. As Joe discussed, our growing commercial activities demonstrate the broad applicability of our C1 and DAPIBUS-based protein production platforms In biopharmaceuticals, we continue to build on the foundation by generating technical and preclinical data involving complex proteins, including monoclonal antibodies and vaccine antigens. Our biopharmaceutical strategy remains focused on externally funded development programs and strategic collaborations rather than independently financing costly clinical development programs. By working with established research institutions, foundations and industry partners, we aim to demonstrate C1's advantages in development, speed, productivity, protein quality, scalability, and manufacturing economics. While advancing its potential adoption by pharmaceutical and biotech companies. Let me highlight 4 important areas of progress.

The first is the Gates Foundation Program's Advance to Animal Studies. Under our approximately $3.1 million Gates funded program C1 achieved productivity yields of approximately 12.1 grams per liter for RSV monoclonal antibody RSV-Mab1, and 13.2 grams per liter for malaria monoclonal antibody Mab1 in 7-day fermentations. Importantly, both C1 produced antibodies demonstrated approximately 90% human-like glycan structures. Supporting C1's ability to produce complex monoclonal antibodies with human relevant glycosylation profiles. Independent evaluations by Duke University and IQVIA also demonstrated binding and neutralization activity comparable to their CHO produced counterparts in the respective assays performed.

Following the quarter end in October, 2026, the Gates Medical Research Institute initiated preclinical animal studies funded directly by the Gates organization comparing the pharmacokinetics of C1 produced RFE and malaria antibodies with the respective GMP CHO-produced counterparts. Results are anticipated in the first quarter of 2027. These studies represent an important next step beyond laboratory testing towards potential clinical development. Together the high production yields, human like glycosylation profiles, and comparable biological functionality supports C1's potential to manufacture complex monoclonal antibodies more efficiently and economically than traditional mammalian cell production platforms. Second, we have completed a rapid vaccine antigen development project, reducing timeline for months to approximately 15 days.

Under the $4.5 million Coalition for epidemic preparedness innovation CEPI funded program with Fondazione Biotecnopolo di Siena FBS, Dyadic developed a rapid C1 production workflow that reduced their previous development timeline from several months to approximately 15 days from plasmid to C tag purified recombinant protein. We initially demonstrated this with our DYAI-100 SARS CoV-2 antigen This progress was put to test during the Bundibugyo Ebola outbreak when we produced and purified 2 scripts, research design antigens in 15 days and delivered them to FVS for preclinical studies. These achievements build on encouraging results across multiple preclinical vaccine programs and our completed phase 1 DYAI-100 clinical trial, which demonstrated safety, tolerability in both humoral and cellular immune responses.

Together, they support C1's potential to accelerate vaccine development and improve responsiveness for emerging infectious disease threats. Third, we have further advanced our monoclonal antibody development and validation. Building on previously published research in Nature Communications, demonstrating the protective efficacy of a C1 produced SARS CoV-2 monoclonal antibody in nonhuman primates we achieved another important milestone with Bundibugyo Ebola. We have demonstrated a rapid development process progressing from plasmid to a clonal production strain and protein a purified Bundibugyo Ebola monoclonal antibody in approximately 7 weeks.

Together with our Gates funded RSV and malaria antibody results, these achievements provide further evidence of C1's ability to rapidly produce biologically functional monoclonal antibody at high yield supporting its potential as an alternative to traditional mammalian cell manufacturing. Finally, we are continuing to advance C1 through third-party funded collaborations involving CEPI, FBS, Scripps Research, the Gates Foundation and the NIAID/NIH supported researchers and others. Through our collaboration with FBS, C1 is also being evaluated within the €170 million Vaccine Hub initiative. With funding awarded at the consortium level rather than directly to Dyadic. These relationships provide valuable opportunities to further evaluate C1 along leading vaccine and biological developers, strengthening its scientific and manufacturing validation and support potential commercial adoption.

As Joe noted, the commercial value of our protein production platforms does not depend on Dyadic independently developing, clinically advancing, or manufacturing every product This is particularly important in biopharmaceuticals where clinical development and commercialization can require substantial capital in specialized infrastructure. Instead, our objective is to leverage the technical results and independent validation generated through these externally funded programs to pursue licensing arrangements funded development programs, technology access agreements, and broader strategic relationships with pharmaceutical and biotechnology companies.

We believe our demonstrated ability to rapidly produce complex vaccine antigens and monoclonal antibodies at high yields while maintaining biological functionality can make C1 an attractive option for organizations seeking faster more scalable, and potentially lower cost alternative to conventional manufacturing technologies. While additional validation and development remains necessary, the ongoing animal studies rapid development milestones, and expanding collaborations continue to strengthen the technical foundation and potential strategic value of C1. Ultimately, our goal is to translate these capabilities into commercial partnerships that can accelerate the development and manufacture of biologic medicines. Strengthen pandemic preparedness, reduce health care costs and expand access to vaccines and therapeutics worldwide.

Together with the commercial progress Joe outlined, we believe these developments position Dyadic to additional opportunities to monetize our technology platforms production capabilities and manufacturing know how. With that, I will turn the call back to Ping for the financial review.

Ping Wang Rawson: Thank you, Mark. I will now go over our key financial results for the third quarter of 26 in more detail You can find additional information in our earnings press release and Form 10-Q which we expect to file as soon as the system is back online. Within the SEC filing deadline. Total revenue for the 3 months ended 09/30/2026 was approximately $449,000 compared to approximately $1.17 million for the third quarter of 25. The decrease of 61% was driven by a $538,000 decline in grant revenue reflecting lower activity under the Gates Foundation and CEPI grant. And a $188,000 decline in research and development revenue as several collaboration projects were completed in the prior year period.

Revenue for the quarter included approximately $162,000 of research and development revenue $276,000 of grant revenue, and $10,000 of license fee revenue. For the first 9 months of 2026, total revenue was $2.5 million essentially flat compared to the same period in 2025. Total cost of revenue for the quarter was approximately $375,000 a decrease of 63% compared to approximately $1.02 million for the last period of 2025. The decrease was primarily related to lower activity levels associated with our grant funded programs. Internal research and development expenses decreased 25% year over year to approximately $430,000 compared to approximately $572,000 in the third quarter of 25.

The decrease reflects $199,000 reduction in third party contract research services as we continue to advance programs through externally funded collaborations and maintain disciplined internal R&D spending. For the 9 months, internal research and development expenses were approximately $1.2 million, down 27% from approximately $1.7 million a year ago. G&A expenses decreased by $31,000 or 2% year-over-year to approximately $1.45 million compared to approximately $1.48 million in the third quarter of 25. For the 9 months, G&A expenses were $4.9 million, an increase of 8.5% year over year. Loss from operations for the quarter was approximately $1.8 million compared to approximately $1.9 million in the prior year period.

Total other income net was approximately $455,000 which includes a non cash net gain of approximately $546,000 from the change in fair value of the warrant liability related to the warrants we issued in our August offering. Net of issuance cost allocated to those warrants. This gain is non cash and it will fluctuate with our share price in future quarters. Net loss for the quarter was approximately $1.4 million, or $0.04 per share, compared to approximately $2 million, or $0.06 per share for the third quarter of 25 For the 9 months, net loss was approximately $5.4 million or $0.15 per share compared to $5.8 million, or $0.18 per share for the first 9 months of 25.

Turning to our balance sheet and cash, we ended the third quarter with approximately $6 million in cash equivalents, restricted cash and the investment grade securities including accrued interest compared to approximately $8.6 million at year end. During the quarter, we completed a registered direct offering with concurrent private placements of warrants which generated gross proceeds of $2.9 million.

On cash usage, net cash used in operating activities was approximately $5.3 million for the first 9 months, or approximately $590,000 per month These figures include the cost of the Gates funded program which are paid from restricted cash We expect our cash usage to continue at a similar level although it will vary from quarter to quarter depending on the timing of and development activities, grant funding and the commercial activities. As we mentioned on the call, we have been actively evaluating financing alternatives and other opportunities to strengthen our balance sheet At the same time, we remain focused on disciplined cash management expanding commercial revenues and leveraging third party funding and strategic collaborations to support development activities.

As Joe discussed, we recorded our first direct commercial product sales in the third quarter and our partners continued to expand the commercialization of products built on our platforms. In addition, following quarter end, enzymes confirmed their first commercial sale of our second chymosin product While these activities are still at an early stage, our objective remains to build recurring products and partnership revenues while carefully managing our operating expenses and the capital requirements. With that, I will now ask the operator to begin our Q&A session. Each caller will be allowed 1 question and 1 follow-up question to provide all callers with an opportunity to participate.

If time permits, the operator will allow additional questions from those who have already spoken. I will now ask the operator to begin our Q&A session. After which Joe Hazleton will provide closing remarks. Operator, Thank you.

Operator: Your first question comes from John Vandermosten-- I am sorry, your first question comes from Talith Korman with Craig Hallum Capital Group. Please state your question.

Talith Korman: This is Talith Korman on for Matthew Hewitt. So circling back to your opening remarks, could you please describe why adoption is progressing slower than initially expected? Thank you.

Joseph Hazelton: So I can take that 1. So the adoption is a little bit slower because there are incorporating into their workflow. So when you are doing cell culture media, let's just say for mammalian cell lines, when you substitute product like, you know, transferrin or even an albumin, you need to ensure that it works in their process before you would transition into your commercial cell line. So that is taking a little bit longer because there is a little more regulatory hurdles for them to overcome.

The research products, though, are picking up because those do not require the same level of, let's just say, regulatory oversight or regulatory scrutiny that some of the products that are used to make human therapeutics are. So while these are not human therapeutic products, they are not actually going into a human being. They are. When you are using it for cell culture media or cell and gene therapy, they are actually being used to produce a human therapeutic. So they do need to evaluate those products to ensure that they meet the quality metrics and perform exactly like the transferrin they are using today so they do not end up obviously with issues.

So that is what is causing the slow. Or at least taking a little bit longer time than we had anticipated for them to do these and obviously incorporate them into workflows.

Talith Korman: Awesome. Great. And then could you speak to anything about like, necessarily just commentary from customers working with your platforms, how they believe it could progress, and their initial thoughts with that? Thank you.

Joseph Hazelton: I think in cell culture, the feedback is very good. So far, the products have been working in cell culture applications. We have received good feedback and even data from some of the customers. Demonstrating in certain models whether it is cultured meat or whether it is mammalian cell lines or even hex cell lines, that are transferring is working. So the feedback has been good that our products are performing as they should, and which is obviously what we hope. And ProLiant has actually put out some very good data on the recombinant human albumin that they are producing using our technology. that is actually performing better than serum derived albumin, you know, that you get from human blood.

So I think the feedback is good, and I think we are we are obviously moving in the right direction. Thank you.

Operator: As a reminder to the audience, to ask a question, press *1. Your next question comes from Dick Williams with Williams Resource Group. Please state your question.

Ana: Yes. Hi, Joe, and hi, this is for you, Joe. In terms of the release that we just came out with a day or so ago, going with the 2 entities in which you have got a partnership of sorts Obviously, I know what I am not sure what you can offer in terms of the sharing arrangements and the revenue that will come out of that partnership. But it looks like the next step is 1 single product. That you mentioned. And that product got a level of around 200 metric tons a year, it looks like is between a $10 million to $16 million business by itself.

So if you can give some more color in that area as to how that triumvirate works. And how we can add additional products to that area that would increase the market opportunity higher than the $10 million to $16 million range.

Joseph Hazelton: that is a great question, Dick. And absolutely, I obviously cannot give, you know, guidance on the, you know, what the financials will look like on it. However, you are exactly right that this is 1 product and 1 end customer. What is different, I guess, with this partnership than previous ones is that Strive Nutrition is the end customer. They have got products in The US market at places like Walmart, CVS, that is where, you know, you will see their products, their free milk products.

And we are essentially, we have now vertically integrated the partnership to include the end And as all of these products are or at least in Strive's case, they are starting to move towards animal free or obviously these higher value proteins for their, you know, nutritional products. There are things like lactoferrin or even human alpha-lactalbumin potentially casein someday. So as you think about alpha-lactalbumin, and I also talked about lactoferrin, those are the follow on products. And remember, Strive is 1 customer, and they are an absolutely wonderful partner. They are going to be testing some of the protein that we are currently producing in application to see how it performs, you know, in their products.

And then, obviously, you know, the goal is that they will they will use it, you know, in their commercial products over time. So our goal, obviously, is to expand that to other potential commercial partners. So it would not just be 1 order of, you know, 200 metric tons. that is that is just for Strive. that is just what they want to use. It could be another 2, 3, 400 metric tons to somebody else. So that is how those systems or those markets grow based on the number of customers you are able to achieve or able to attain you know, over time, and then the number of products that they are putting into their different formulation.

So depending on whether they are working on, let's say, early life, or infant nutrition or healthy aging, those type of products, those all have different amounts of different proteins, whether it is alpha lactoferrin, casings, beta lactoglobulin, It all depends on the products they are they are looking to make. And again, it differs between customer, but this is just 1 customer and, obviously, a great partner to start the process off with. Okay. Thanks, Joe.

Ana: I have 1 question for Mark.

Mark A. Emalfarb: Mark, in terms of the things that we have just finished, it seems like we have made a milestone in terms of the announcement and that the next step for the antibodies is proceeding. Can you give us some color on where that is going, the timeline to go next steps for the 2 areas of disease that you have now been involved with here? Yeah. So thanks, Jack. Mean, first of all, the antibody program you know, as I mentioned, there is 3 legs that are still going on right now.

1 was in COVID, of course, we demonstrated beyond a mice study we actually went to non human primates and it demonstrated safety, efficacy, everything else performance equal to the existing system we just did not get the money from the European Union to get it into humans at that point. With the Gates Foundation, the malaria antibody and the RSV antibodies, the beautiful thing there is the gates have the deep pocket that if this continues to proceed as it is, we. Next step would hopefully be able to put it into then going from the mice studies to a nonhuman primate and then ultimately to human beings.

And it is really a major milestone because the yield that they are seeing and if you would ask them and of course they highlighted this are astronomical compared to what they are getting out of the CHO cells and half the time. So the cost of goods is really critical to them to get into these lower middle income countries. But that same technology platform is going to be used and applied in neurology, oncology, and immunology. In this $500 billion market of monoclonal antibodies if we can crack the code, which means right quality at the right price at the right cost, and it is a faster quicker way of doing that.

And that takes us to the gates or the CEPI program with the European Vaccine Hub,, and all the work going on there. But we have shortened the timeline dramatically to address pandemics it is also shorter to develop into the animal studies and into the clinical trials to get there faster. So we are able to produce more quicker, faster, cheaper, and release it sooner. So it is a great thing And the Gates Foundation providing that they continue to see the excellent results of the human glycosylation, how they perform in the pharmacogenetic studies that are ongoing. And that data is due in Q1 this year.

We hope to follow that up and we already have the money sitting in the bank and move it to the next level. This particular animal study was actually funded by Gates MRI, and we did not have to use the money that we already have to do that. So we are very excited about all these opportunities. We took the Ebola antibody, which is something that we also did very rapidly with the European Vaccine Hub, and Reno Rapioli. Hopefully sometime in the next few months we will start getting some data on that. So demonstrated speed that the world needs to meet the needs of a demand of a pandemic without mRNA.

We believe that our cost structures give significant advantages. And everything's moving in the right direction. Unfortunately, it is slower than everyone would like. We do not have the money just to push it on our own, and we are relying on third party to do it. And we have got the right third parties that have the expertise from a regulatory perspective from a commercial perspective, it is it is all going well. So, hopefully, that helps out. Thank you.

Operator: And your next question comes from John Vandermosten with Zacks. Please state your question.

John Vandermosten: Great. Thank you and good evening everyone. Let me start out with a question on product sales. They were modest in the third quarter. But I am wondering is that a good baseline as we look forward to Q4 and in 2027? You guys mentioned you had chymosin sales in November. How should we look at that and think about, you know, maybe building off a small base?

Joseph Hazelton: Well, I think you should know that it is. it is building off a small base and you know, 1 of the things we do not have a lot of, you know, capital to basically put a lot of inventory out into the market. So that is 1 of the issues and 1 of the reasons that we are growing slowly. Like, we have not been able to you know, fill channels to a significant level. We are we are kind of making to demand right now. So that is 1 of the reasons that this is growing slower than we would have liked You know, ordinarily, you would obviously create a lot of products.

And you do that at your own cost, you would put it into the market and over time, obviously, it would sell. So we have other distributors that could take product We just need to, again, get it made and get it there, but we do not have the money to do that. So banking it to demand is 1 of the reasons that is taking longer than we would have liked in the research segment. But now that it is starting to pick up, we are hoping that will start to grow a little bit faster. We are also. Now that the products are out and now that we have commercialized products both with Prolyant, both with.

And as well as with enzymes, we are approaching larger companies. Because now we have derisked the platforms and we have derisked the product. They are being used in research. They are being used in food applications. They are now being used in cell culture. So now we are also getting data back in from a lot of the evaluations that are being done and some of the companies that have already bought That data is going back into building a better basically, product monograph or whether it is transferring or whether it is DNase 1. And we are hoping that will spur larger orders with larger customers.

So that. that is 1 of the main things for us is focusing on customers that can take large scale orders and large scale supply agreements. And can fund actual manufacturing. So it is going to be a little slow. But the good news is it is starting to sell. it is starting to move. We just need to try to accelerate with larger customers that will actually put some money in upfront. And that can fund some of the manufacturing that we need to do. Okay. Thanks, Joe.

John Vandermosten: And then, you know, as we look at the STRiVE agreement, how was that agreement structured? I know you have you have had a different kinds of structures in terms of, like, royalty or profit share. What is that 1?

Joseph Hazelton: This 1 is a supply agreement. So that. that is essentially what to think about as a agreement. Right now, we are developing and optimizing the strain. As we produce some of the protein, it will be tested by STRiVE. They are gonna test it in make sure that it performs digestibility studies. And the things that they will wanna do for their own products. And then once we meet the economic, threshold and regulatory threshold, which is a self affirmed grasp, I think we have that in the press release. And once we meet the economic thresholds of the agreement we signed, then the purchases will follow.

So the initial is for 10 tons and then up to 100 tons in the following year. So if should ramp very quickly depending on how fast we can get to the right optimized yield for the product, bringing the cost to where it needs to be for these applications. But, hopefully, that will happen quickly. Thank you.

Mark A. Emalfarb: And I think, Joe, maybe you can talk about, again, as you mentioned earlier, STRiVE is 1 of many customers and 1 of the largest that we are in discussions with.

Joseph Hazelton: Yeah. And they are an excellent customer. They do have, obviously, national distribution here in The US. But Mark's right. There are other customers that are looking for alpha-lactalbumin and definitely for different uses. STRiVE is in essentially, healthy nutrition, sports nutrition, They are looking at, you know, potentially getting into, you know, healthy aging and other segments. But there are companies looking at this for early life, infant nutrition that, again, could be, you know, could be an interesting opportunity. But there are tons of companies in the non animal dairy space. Thank you.

Operator: And there are no further questions. I will now turn the call over to Dyadic President and COO, Joe Hazleton.

Joseph Hazelton: Thank you, and thank you everyone who joined us today. As we close, I want to reinforce the direction we are taking for Dyadic. We continue to make progress commercializing our technologies, both through our own product sales and through our partners, who successfully brought products developed using our platforms to market. These activities remain early, and we recognize that building meaningful recurring commercial revenue will take additional time and execution. However, we believe the combination of commercial experience improving production capabilities, and externally validated technical performance provides a stronger foundation for the next stage of Dyadic's development. Our focus is increasingly on how to translate those capabilities into larger commercial and strategic opportunities.

We believe the greatest potential value of our platforms may be realized by working with companies that have the resources, manufacturing infrastructure, and market access to commercialize our products and technologies at scale. That includes licensing and supply relationships, broader strategic partnerships, and other potential transactions that can strengthen our financial position and accelerate the commercial development of our assets. We recognize the importance of moving with great urgency, prioritizing our resources, and pursuing opportunities that can deliver meaningful value for shareholders. Our objective is to build on the technical and commercial foundation we have established and identify the most effective path to realize its value.

We appreciate the continued support of our shareholders and partners and employees and we look forward to updating you on our progress. Thank you, everyone.

Operator: This conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines at this time.

Should you buy stock in Dyadic International right now?

Before you buy stock in Dyadic International, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dyadic International wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $338,083!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,021,163!*

Now, it’s worth noting Stock Advisor’s total average return is 830% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 13, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.
Visit Fool.com for more market news More articles by this source

Tags

Stocks Mentioned

Latest Articles

Data is currently not available